AIMS: Nuclear factor E2-related factor 2 (Nrf2), a key cytoprotective transcription factor, regulates also proangiogenic mediators, interleukin-8 and heme oxygenase-1 (HO-1). However, hitherto its role in blood vessel formation was modestly examined. Particularly, although Nrf2 was shown to affect hematopoietic stem cells, it was not tested in bone marrow-derived proangiogenic cells (PACs). Here we investigated angiogenic properties of Nrf2 in PACs, endothelial cells, and inflammation-related revascularization. RESULTS: Treatment of endothelial cells with angiogenic cytokines increased nuclear localization of Nrf2 and induced expression of HO-1. Nrf2 activation stimulated a tube network formation, while its inhibition decreased angiogenic response of human endothelial cells, the latter effect reversed by overexpression of HO-1. Moreover, lack of Nrf2 attenuated survival, proliferation, migration, and angiogenic potential of murine PACs and affected angiogenic transcriptome in vitro. Additionally, angiogenic capacity of PAC Nrf2(-/-) in in vivo Matrigel assay and PAC mobilization in response to hind limb ischemia of Nrf2(-/-) mice were impaired. Despite that, restoration of blood flow in Nrf2-deficient ischemic muscles was better and accompanied by increased oxidative stress and inflammatory response. Accordingly, the anti-inflammatory agent etodolac tended to diminish blood flow in the Nrf2(-/-) mice. INNOVATION: Identification of a novel role of Nrf2 in angiogenic signaling of endothelial cells and PACs. CONCLUSION: Nrf2 contributes to angiogenic potential of both endothelial cells and PACs; however, its deficiency increases muscle blood flow under tissue ischemia. This might suggest a proangiogenic role of inflammation in the absence of Nrf2 in vivo, concomitantly undermining the role of PACs in such conditions.
AIMS: Nuclear factor E2-related factor 2 (Nrf2), a key cytoprotective transcription factor, regulates also proangiogenic mediators, interleukin-8 and heme oxygenase-1 (HO-1). However, hitherto its role in blood vessel formation was modestly examined. Particularly, although Nrf2 was shown to affect hematopoietic stem cells, it was not tested in bone marrow-derived proangiogenic cells (PACs). Here we investigated angiogenic properties of Nrf2 in PACs, endothelial cells, and inflammation-related revascularization. RESULTS: Treatment of endothelial cells with angiogenic cytokines increased nuclear localization of Nrf2 and induced expression of HO-1. Nrf2 activation stimulated a tube network formation, while its inhibition decreased angiogenic response of human endothelial cells, the latter effect reversed by overexpression of HO-1. Moreover, lack of Nrf2 attenuated survival, proliferation, migration, and angiogenic potential of murinePACs and affected angiogenic transcriptome in vitro. Additionally, angiogenic capacity of PACNrf2(-/-) in in vivo Matrigel assay and PAC mobilization in response to hind limb ischemia of Nrf2(-/-) mice were impaired. Despite that, restoration of blood flow in Nrf2-deficient ischemic muscles was better and accompanied by increased oxidative stress and inflammatory response. Accordingly, the anti-inflammatory agent etodolac tended to diminish blood flow in the Nrf2(-/-) mice. INNOVATION: Identification of a novel role of Nrf2 in angiogenic signaling of endothelial cells and PACs. CONCLUSION:Nrf2 contributes to angiogenic potential of both endothelial cells and PACs; however, its deficiency increases muscle blood flow under tissue ischemia. This might suggest a proangiogenic role of inflammation in the absence of Nrf2 in vivo, concomitantly undermining the role of PACs in such conditions.
Authors: E W Ades; F J Candal; R A Swerlick; V G George; S Summers; D C Bosse; T J Lawley Journal: J Invest Dermatol Date: 1992-12 Impact factor: 8.551
Authors: Gennaro Galasso; Stephan Schiekofer; Kaori Sato; Rei Shibata; Diane E Handy; Noriyuki Ouchi; Jane A Leopold; Joseph Loscalzo; Kenneth Walsh Journal: Circ Res Date: 2005-12-22 Impact factor: 17.367
Authors: M Noa Valcarcel-Ares; Tripti Gautam; Junie P Warrington; Lora Bailey-Downs; Danuta Sosnowska; Rafael de Cabo; Gyorgy Losonczy; William E Sonntag; Zoltan Ungvari; Anna Csiszar Journal: J Gerontol A Biol Sci Med Sci Date: 2012-01-04 Impact factor: 6.053
Authors: Magdalena Kozakowska; Maciej Ciesla; Anna Stefanska; Klaudia Skrzypek; Halina Was; Agnieszka Jazwa; Anna Grochot-Przeczek; Jerzy Kotlinowski; Agnieszka Szymula; Aleksandra Bartelik; Milena Mazan; Oleksandr Yagensky; Urszula Florczyk; Krzysztof Lemke; Anna Zebzda; Grzegorz Dyduch; Witold Nowak; Krzysztof Szade; Jacek Stepniewski; Marcin Majka; Rafal Derlacz; Agnieszka Loboda; Jozef Dulak; Alicja Jozkowicz Journal: Antioxid Redox Signal Date: 2011-10-19 Impact factor: 8.401
Authors: Tongrong He; Timothy E Peterson; Ekhson L Holmuhamedov; Andre Terzic; Noel M Caplice; Larry W Oberley; Zvonimir S Katusic Journal: Arterioscler Thromb Vasc Biol Date: 2004-08-19 Impact factor: 8.311
Authors: Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner Journal: Nat Med Date: 2004-07-04 Impact factor: 53.440
Authors: Antonio D'Amore; Marco Fazzari; Hong-Bin Jiang; Samuel K Luketich; Michael E Luketich; Richard Hoff; Daniel L Jacobs; Xinzhu Gu; Stephen F Badylak; Bruce A Freeman; William R Wagner Journal: Tissue Eng Part A Date: 2018-02-27 Impact factor: 3.845
Authors: Tihomir Miralem; Nicole Lerner-Marmarosh; Peter E M Gibbs; Jermaine L Jenkins; Chelsea Heimiller; Mahin D Maines Journal: FASEB J Date: 2016-05-10 Impact factor: 5.191
Authors: Xiaozhen Dai; Xiaoqing Yan; Jun Zeng; Jing Chen; Yuehui Wang; Jun Chen; Yan Li; Michelle T Barati; Kupper A Wintergerst; Kejian Pan; Matthew A Nystoriak; Daniel J Conklin; Gregg Rokosh; Paul N Epstein; Xiaokun Li; Yi Tan Journal: Circ Res Date: 2017-01-30 Impact factor: 17.367